Diaceutics held its Capital Markets Event (CME) yesterday. This was not an event that set out new targets or strategy but rather served to emphasise the leading position Diaceutics occupies in the precision medicine ecosystem and therefore confirmed its growth potential. In addition, the CME added colour to the scale of development that has taken place in the capability of the DXRX platform over the last 18 months as well as emphasising the substantial changes in organisation designed to improve the company's ability to market itself more widely and deeply across the precision medicine opportunity in pharma, biotech, and also life sciences to help find patients and thereby deliver better treatment outcomes.
![working](/images/WorkingLarge.gif)
13 Jun 2024
Diaceutics | CME confirms Diaceutics market leading position
![](/images/orange-lock.png)
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Diaceutics | CME confirms Diaceutics market leading position
Diaceutics Plc (DXRX:LON) | 120 0 0.0% | Mkt Cap: 101.7m
- Published:
13 Jun 2024 -
Author:
Colin Smith -
Pages:
6 -
Diaceutics held its Capital Markets Event (CME) yesterday. This was not an event that set out new targets or strategy but rather served to emphasise the leading position Diaceutics occupies in the precision medicine ecosystem and therefore confirmed its growth potential. In addition, the CME added colour to the scale of development that has taken place in the capability of the DXRX platform over the last 18 months as well as emphasising the substantial changes in organisation designed to improve the company's ability to market itself more widely and deeply across the precision medicine opportunity in pharma, biotech, and also life sciences to help find patients and thereby deliver better treatment outcomes.